Cryoglobulinemia Diagnosis and Treatment

Diagnostic Approach

The American Association for the Study of Liver Diseases recommends screening all HCV-positive patients at initial CKD evaluation using immunoassay followed by nucleic acid testing if positive 1
Patients presenting with the classic triad: purpura, weakness, and arthralgias, should be tested for cryoglobulinemia 2, 3
Evaluate patients with unexplained cutaneous vasculitis, glomerulonephritis, or peripheral neuropathy for cryoglobulinemia 2, 3
Repeat testing if initial results are negative but clinical suspicion remains high, as cryoglobulin levels fluctuate and may be temporarily undetectable 2, 3, 4
Check complement C4 levels, which are typically low in mixed cryoglobulinemia 2, 3
Exclude other infectious causes, autoimmune diseases, and hematologic malignancies 2, 3

For HCV-related cryoglobulinemia with mild symptoms, the European Association for the Study of the Liver recommends direct-acting antivirals targeting HCV eradication as first-line therapy 1
Patients with cryoglobulinemic flare, rapidly progressive glomerulonephritis, or severe organ involvement require immediate combined immunosuppression plus DAAs, not antivirals alone 1
Rituximab is first-line immunosuppressive therapy, with 70-90% renal response rates in cryoglobulinemic nephritis 1
Patients with HCV-associated glomerulonephritis and stable kidney function without nephrotic syndrome should receive DAAs before other treatments 1
Use both DAAs and immunosuppressive agents with or without plasma exchange for rapidly progressive glomerulonephritis 1
If histologically active disease persists despite antiviral therapy, add immunosuppression with rituximab as first-line agent 1

Test kidney transplant recipients every 6 months for proteinuria 1
Do not rely on single negative cryoglobulin test when clinical suspicion is high 2, 3, 4
Do not delay immunosuppression in severe disease while waiting for antiviral response 1

Cryoglobulins are immunoglobulins that precipitate when cooled below 37°C and re-dissolve when heated, resulting in temperature-dependent clinical manifestations, as noted by Haematologica 5

Type I cryoglobulinemia is frequently associated with lymphoproliferative disorders such as Waldenström macroglobulinemia, according to the Journal of the National Comprehensive Cancer Network 6
Type II cryoglobulinemia contains monoclonal immunoglobulins with rheumatoid factor activity and is often associated with HCV infection, as reported by Autoimmunity Reviews 7 and 8
HCV infection is the most common cause of mixed cryoglobulinemia, found in 70-90% of patients with cryoglobulinemic vasculitis, as stated by Autoimmunity Reviews 8

Temperature-dependent symptoms such as Raynaud phenomenon, acrocyanosis, and cold urticaria are due to precipitation of cryoglobulins in cooler body areas, as described by Haematologica 5
Meltzer's triad, a classic presentation, includes purpura, weakness, and arthralgias, according to Autoimmunity Reviews 9
Systemic manifestations can include peripheral neuropathy, renal failure, and skin vasculitis, as reported by Autoimmunity Reviews 7 and 8

The American College of Physicians and other guideline societies recommend treatment of the underlying cause, such as eradication of HCV using direct-acting antivirals for mild to moderate disease, as suggested by Autoimmunity Reviews 7
Immunosuppression with rituximab combined with glucocorticoids is often effective for severe manifestations, as noted by Autoimmunity Reviews 9
Plasmapheresis is a first-line treatment for hyperviscosity syndrome and can rapidly reduce circulating cryoglobulins, according to Autoimmunity Reviews 9